Seeking Alpha

Eli Lilly (LLY +0.5%) ups its FY net EPS forecast to $3.72-$3.82 to reflect income from the...

Eli Lilly (LLY +0.5%) ups its FY net EPS forecast to $3.72-$3.82 to reflect income from the early payment of $1.26B in revenue share from Amylin Pharmaceuticals - which has just been bought by Bristol-Myers Squibb - in connection with exenatide, a treatment for diabetes. Eli Lilly keeps its adjusted EPS unchanged at $3.30-$3.40 vs. forecasts of $3.37. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs